| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Protein |
| Molecule Category: | UNKNOWN |
| UNII: | GZ8FA500J0 |
| InChI Key | NSQLIUXCMFBZME-MPVJKSABSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C127H203N45O39S3 |
| Molecular Weight | 3080.5 |
| AlogP | None |
| Hydrogen Bond Acceptor | None |
| Hydrogen Bond Donor | None |
| Number of Rotational Bond | None |
| Polar Surface Area | None |
| Molecular species | None |
| Aromatic Rings | None |
| Heavy Atoms | None |
| Action | Mechanism of Action | Reference |
|---|---|---|
| AGONIST | Atrial natriuretic peptide receptor agonist | PubMed |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Lyase
Guanylate cyclase
Receptor guanylate cyclase
|
0 | - | - | - | - | |
|
Membrane receptor
|
1 | - | - | - | - |
| Mesh Heading | Maximum Phase | Reference |
|---|---|---|
| Cardiomyopathies; Heart Failure; Ventricular Dysfunction; Ventricular Dysfunction, Left | Phase 2 | ClinicalTrials |
| Resources | Reference |
|---|---|
| ChEBI | 135914 |
| ChEMBL | CHEMBL2104386 |
| DrugCentral | 515 |
| FDA SRS | GZ8FA500J0 |
| SureChEMBL | SCHEMBL218549 |